# Prognyx

> Continuous, sourced competitive intelligence for oncology. Trials, readouts,
> deals and regulatory moves, mapped to your pipeline. Oncology only.

Prognyx writes analyst briefings for small and mid-size oncology biotechs that
compete in crowded mechanism classes. Every claim is cited to a primary source.

## Core pages

- [Prognyx homepage](https://www.prognyx.com/): what the service is and how it works.
- [About Prognyx, who writes the briefings | Prognyx](https://www.prognyx.com/about): Rali Filali designs the method behind every Prognyx oncology briefing and sets the audit bar it has to clear. One named person, one published procedure.
- [Citeline Alternative for Oncology Biotech | Prognyx](https://www.prognyx.com/alternatives/citeline): Citeline curates Pharmaprojects and Trialtrove for your analysts; Prognyx delivers the oncology read itself. Honest comparison, including when Citeline wins.
- [GlobalData Alternative for Oncology CI | Prognyx](https://www.prognyx.com/alternatives/globaldata): GlobalData forecasts markets across all of pharma; Prognyx reads one oncology competitive set and tells you what to do. Including when GlobalData is right.
- [Beacon Alternative for Oncology CI | Prognyx](https://www.prognyx.com/alternatives/beacon): Beacon curates oncology drug and trial data at depth; Prognyx reads one competitive set and writes the conclusion. Including when Beacon is the better buy.
- [In-House CI Analyst vs Outsourced CI | Prognyx](https://www.prognyx.com/alternatives/in-house-ci-analyst): Loaded cost, hiring lag and departure risk versus an outsourced pilot, an honest comparison, including when hiring in-house is clearly the right call.
- [Cortellis Alternative for Small Biotech | Prognyx](https://www.prognyx.com/alternatives/cortellis): An honest comparison: Cortellis is a data platform your analysts work inside; Prognyx is delivered oncology CI. Including when Cortellis is the better buy.
- [AlphaSense Alternative for Oncology CI | Prognyx](https://www.prognyx.com/alternatives/alphasense): AlphaSense finds the passage; Prognyx decides what it means for your asset. Honest comparison for oncology biotechs, including when AlphaSense wins.
- [Competitive Intelligence Tools for Small Biotech](https://www.prognyx.com/competitive-intelligence-tools-small-biotech): The honest stack for oncology competitive intelligence with no CI team and no platform budget: what is free, what it covers, where it stops working.
- [PD-1 x VEGF Bispecifics: Competitive Landscape](https://www.prognyx.com/landscapes/pd1-vegf-bispecifics): Every PD-1 x VEGF bispecific in late development, with the registry record and the regulatory action behind each one. Reviewed 1 September 2026, kept current.
- [KRAS G12C Inhibitors: Competitive Landscape](https://www.prognyx.com/landscapes/kras-g12c): Sotorasib, adagrasib, divarasib, olomorasib, fulzerasib and the RAS(ON) generation, approvals, trials and evidence, sourced. Reviewed 1 September 2026.
- [Live oncology trial landscape | Prognyx](https://www.prognyx.com/live-landscape): Explore oncology trials live from ClinicalTrials.gov, with a sourced AI reading and related Prognyx briefs. Free, no sign-up.
- [Prognyx MCP server: oncology trials in your AI | Prognyx](https://www.prognyx.com/mcp): In Claude's connector directory: compare oncology trials around an asset, map trial landscapes and search Prognyx briefings. Free and read-only.
- [How We Work, Prognyx Methodology & Sourcing Rules | Prognyx](https://www.prognyx.com/methodology): The procedure behind every Prognyx briefing: one primary source per fact, a separate audit pass, a freshness gate, and a published bar it has to clear.
- [The Watchtower by Email, Oncology Briefings | Prognyx](https://www.prognyx.com/newsletter): Get each Prognyx oncology competitive-intelligence briefing by email the day it publishes. Double opt-in, one email per briefing, unsubscribe in one click.
- [See a Sample Oncology Competitive Brief (PDF) | Prognyx](https://www.prognyx.com/sample-brief): Read an actual Prognyx competitive brief before talking to anyone: what is in it, how each claim is sourced, and the PDF itself. One email, no sales sequence.
- [Oncology Competitive Intelligence Service | Prognyx](https://www.prognyx.com/oncology-competitive-intelligence): A one-off oncology competitive-intelligence pilot: one asset, one indication and one decision-ready brief, delivered in five business days.
- [What Is Prognyx? Definition, Founder, Scope](https://www.prognyx.com/what-is-prognyx): Prognyx is the outsourced competitive-intelligence function for clinical-stage oncology biotechs without an internal CI team. Founder, scope, base, sources.

## Recent briefings

- [Amgen's Imdelltra plus Imfinzi cuts death risk 58% in first-line ES-SCLC](https://www.prognyx.com/blog/amgen-s-imdelltra-plus-imfinzi-cuts-death-risk-58-in-first-line-es-sclc): 2026-10-24T15:15:40.522Z
- [Innovent's arcotatug tavatecan clears OS and PFS in Phase 3 gastric cancer at ESMO](https://www.prognyx.com/blog/innovent-s-arcotatug-tavatecan-clears-os-and-pfs-in-phase-3-gastric-cancer-at-es): 2026-10-23T15:11:57.160Z
- [Keytruda-Padcev wins EU approval for resectable bladder cancer, any cisplatin status](https://www.prognyx.com/blog/keytruda-padcev-wins-eu-approval-for-resectable-bladder-cancer-any-cisplatin-sta): 2026-10-21T15:12:03.479Z
- [FDA accelerated approval: GSK's Jemperli, first immunotherapy for dMMR rectal cancer](https://www.prognyx.com/blog/fda-accelerated-approval-gsk-s-jemperli-first-immunotherapy-for-dmmr-rectal-canc): 2026-10-20T15:13:00.500Z
- [Riboscience to present RBS2418's first overall-survival data at ESMO 2026](https://www.prognyx.com/blog/riboscience-to-present-rbs2418-s-first-overall-survival-data-at-esmo-2026): 2026-10-19T15:08:24.015Z
- [CHMP backs a label change for Janssen's myeloma bispecific Talvey](https://www.prognyx.com/blog/chmp-backs-a-label-change-for-janssen-s-myeloma-bispecific-talvey): 2026-10-17T15:12:57.899Z
- [Verastem's VS-7375 hits 50% response in second-line pancreatic cancer, Phase 3 next](https://www.prognyx.com/blog/verastem-s-vs-7375-hits-50-response-in-second-line-pancreatic-cancer-phase-3-nex): 2026-10-16T15:15:39.739Z
- [FDA expands ImmunityBio's Anktiva label to papillary-only NMIBC](https://www.prognyx.com/blog/fda-expands-immunitybio-s-anktiva-label-to-papillary-only-nmibc): 2026-10-15T15:14:52.664Z
- [Gilead pays Vir $90M upfront for three masked T-cell engagers in solid tumors](https://www.prognyx.com/blog/gilead-pays-vir-90m-upfront-for-three-masked-t-cell-engagers-in-solid-tumors): 2026-10-14T15:10:39.008Z
- [Intismeran autogene improves RFS and DMFS in resected melanoma, Merck says](https://www.prognyx.com/blog/intismeran-autogene-improves-rfs-and-dmfs-in-resected-melanoma-merck-says): 2026-10-13T15:10:49.919Z
- [T-MAXIMUM wins FDA clearance for a Phase 2 CAR-T trial in brain metastases](https://www.prognyx.com/blog/t-maximum-wins-fda-clearance-for-a-phase-2-car-t-trial-in-brain-metastases): 2026-10-12T15:13:27.071Z
- [FDA approves atezolizumab plus chemo for adjuvant Stage III dMMR colon cancer](https://www.prognyx.com/blog/fda-approves-atezolizumab-plus-chemo-for-adjuvant-stage-iii-dmmr-colon-cancer): 2026-10-09T15:09:58.977Z
- [FDA approves Pfizer's tucatinib triplet for HER2-positive breast cancer maintenance](https://www.prognyx.com/blog/fda-approves-pfizer-s-tucatinib-triplet-for-her2-positive-breast-cancer-maintena): 2026-10-08T15:23:03.424Z
- [AbbVie's c-Met ADC wins dual FDA Breakthrough Therapy tags in CRC and lung cancer](https://www.prognyx.com/blog/abbvie-s-c-met-adc-wins-dual-fda-breakthrough-therapy-tags-in-crc-and-lung-cance): 2026-10-07T15:08:54.834Z
- [Epcoritamab plus R-CHOP cuts first-line DLBCL progression risk 51% in Phase 3](https://www.prognyx.com/blog/epcoritamab-plus-r-chop-cuts-first-line-dlbcl-progression-risk-51-in-phase-3): 2026-10-06T15:32:23.560Z

- [All briefings](https://www.prognyx.com/blog)
- [RSS feed](https://www.prognyx.com/blog/feed.xml): the 30 most recent briefings, RSS 2.0.

## Drug files

Every Prognyx briefing on one compound, dated, with a timeline of sourced events.

- [Daraxonrasib: Briefings and Sourced Timeline](https://www.prognyx.com/drug/daraxonrasib)
- [Ivonescimab: Briefings and Sourced Timeline](https://www.prognyx.com/drug/ivonescimab)
- [Pembrolizumab: Briefings and Sourced Timeline](https://www.prognyx.com/drug/pembrolizumab)
- [Trastuzumab deruxtecan: Briefings and Sourced Timeline](https://www.prognyx.com/drug/trastuzumab-deruxtecan)
- [Zipalertinib: Briefings and Sourced Timeline](https://www.prognyx.com/drug/zipalertinib)

## Detail

- [Full description](https://www.prognyx.com/llms-full.txt): positioning, scope, methodology,
  and how Prognyx compares to Cortellis and AlphaSense.

## Contact

- hello@prognyx.com

Last updated: 2026-10-24